Acromegaly Pipeline Insights and Key Players – 2020

July 31 21:42 2020
Acromegaly Pipeline Insights and Key Players - 2020

DelveInsight Business Research LLP
Acromegaly Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acromegaly market. A detailed picture of the Acromegaly pipeline landscape is provided, which includes the disease overview and Acromegaly treatment guidelines.

Acromegaly is a rare and chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma.

 

Acromegaly Emerging Drugs

 

  1. IONIS-GHR-LRx: Ionis Pharmaceuticals
  2. Mycapssa (Octreotide Capsules): Chiasma Pharma
  3. ATL1103: Antisense Therapeutics
  4. CAM2029: Camurus
  5. GT-02037 (G-SRIF): GlyTech
  6. Veldoreotide (COR-005, DG3173): Strongbridge Biopharma
  7. Paltusotine (CRN00808): Crinetics Pharmaceuticals
  8. MTD201: Midatech
  9. Lanreotide PRF: Ipsen

Scope of the Report

  • The Acromegaly report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Acromegaly across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Acromegaly therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Acromegaly research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Acromegaly.

 

Request for sample pages

Table of contents

1. Report Introduction

2. Acromegaly 

2.1. Overview

2.2. History 

2.3. Acromegaly Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Acromegaly Diagnosis 

2.6.1. Diagnostic Guidelines

3. Acromegaly Current Treatment Patterns

3.1. Acromegaly Treatment Guidelines

4. Acromegaly – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Acromegaly Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Acromegaly Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Acromegaly Late Stage Products (Phase-III)

7. Acromegaly Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acromegaly Discontinued Products

13. Acromegaly Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Acromegaly Key Companies

15. Acromegaly Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Acromegaly Unmet Needs

18. Acromegaly Future Perspectives

19. Acromegaly Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/